Nicole Basset-Seguin is an expert in Dermatology at Hôpital Saint-Louis (France). As of October 2026, ScienceLeadR ranks Nicole Basset-Seguin in the top 1% of experts worldwide for Non-Melanoma Skin Neoplasms, Skin Neoplasms and Carcinoma. Nicole Basset-Seguin has authored 360 publications, the most recent in 2025, and is an investigator in 9 clinical trials. SLR score: 1,152 (community average: 125). How the SLR is computed.

LeadR Profile

Nicole Basset-Seguin Hôpital Saint-Louis France
1 152 ScienceLeadR Reputation 1152
Network Map

Dermatology

Subspecialties: Oncology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1987 - 2025

Source: PubMed

Hôpital Saint-Louis

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 360

Citations

Citations: 10 924 1st author: 47 Last author: 66 Unique author: 12


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Genomic and clinical characterization of anogenital basal cell carcinoma: A retrospective and prospective cohort study.
PMID 40854498 — cells, cohort studies, vulva, dermatology, mutation, carcinoma, basal cell
J Am Acad Dermatol20250
Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma.
PMID 40454639 — cells, disease-free survival, carcinoma, squamous cell, respect, therapeutics, cutaneous squamous cell carcinoma
N Engl J Med Top journal202530
Operational classification of cutaneous squamous cell carcinomas based on unsupervised clustering of real cases by experts.
PMID 38961704 — cells, sexually transmitted diseases, carcinoma, squamous cell, classification, skin diseases, cluster analysis, therapeutics
J Eur Acad Dermatol Venereol20242
Re-evaluation of the concept of basaloid follicular hamartoma associated with naevoid basal cell carcinoma syndrome: a morphological, immunohistochemical and molecular study.
PMID 39455322 — skin, cells, pathology, mutation, carcinoma, basal cell, hamartoma
Pathology20240
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2024.
PMID 39709737 — antibodies, melanoma, neoplasms, immunotherapy, lymph, nivolumab, therapeutics, ipilimumab, mutation
Eur J Cancer202411

Clinical Studies 9

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

Phase 2 6
Phase 3 3

By status:

Completed 8
Active not recruiting 1

By type:

Interventional 9

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 0
multicentric5to9 0
multicentricup10 8

Main Topics

Cohort/Consortium Investigators 1

LeadR Networks

Main global connection map